Caribou Bioscience (CRBU) announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou’s four clinical programs for hematologic malignancies and autoimmune diseases. Dr. Albertson will report to Rachel Haurwitz, PhD, Caribou’s president and chief executive officer. Albertson was most recently the chief medical officer and head of development for Lyell Immunopharma (LYEL)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
- Caribou Biosciences reports Q2 EPS (42c), consensus (46c)
- Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
- Caribou Biosciences appoints Terri Laufer to Scientific Advisory Board